600062 华润双鹤
交易中 03-11 14:55:35
资讯
新帖
简况
“体重管理年”刷屏,是为了滞销的减肥药吗?
医药财经 · 03-10 15:31
“体重管理年”刷屏,是为了滞销的减肥药吗?
华润双鹤控股子公司阿齐沙坦原料药获批上市
财中社 · 03-06
华润双鹤控股子公司阿齐沙坦原料药获批上市
华润双鹤最新公告:控股子公司浙江新赛科阿齐沙坦原料药获得化学原料药上市申请批准通知书
证券之星 · 03-06
华润双鹤最新公告:控股子公司浙江新赛科阿齐沙坦原料药获得化学原料药上市申请批准通知书
华润双鹤(600062.SH)子公司阿齐沙坦原料药获得化学原料药上市申请批准通知书
智通财经 · 03-06
华润双鹤(600062.SH)子公司阿齐沙坦原料药获得化学原料药上市申请批准通知书
华润双鹤:控股子公司阿齐沙坦原料药获上市批准
美港电讯 · 03-06
华润双鹤:控股子公司阿齐沙坦原料药获上市批准
华润双鹤03月05日主力净流出20万元 散户资金买入
市场透视 · 03-05
华润双鹤03月05日主力净流出20万元 散户资金买入
华润双鹤03月04日主力净流入3137万元 散户资金抛售
市场透视 · 03-04
华润双鹤03月04日主力净流入3137万元 散户资金抛售
华润双鹤:左乙拉西坦口服溶液获药品注册证书
智通财经 · 03-03
华润双鹤:左乙拉西坦口服溶液获药品注册证书
华润双鹤(600062.SH):左乙拉西坦口服溶液获药品注册证书
智通财经 · 03-03
华润双鹤(600062.SH):左乙拉西坦口服溶液获药品注册证书
华润双鹤(600062.SH):天东制药通过GMP符合性检查
智通财经 · 03-03
华润双鹤(600062.SH):天东制药通过GMP符合性检查
华润双鹤:产品取得注册证
每日经济新闻 · 03-03
华润双鹤:产品取得注册证
华润双鹤最新公告:控股子公司东营天东制药有限公司通过GMP符合性检查
证券之星 · 03-03
华润双鹤最新公告:控股子公司东营天东制药有限公司通过GMP符合性检查
华润双鹤最新公告:控股子公司湘中制药左乙拉西坦口服溶液获得药品注册证书
证券之星 · 03-03
华润双鹤最新公告:控股子公司湘中制药左乙拉西坦口服溶液获得药品注册证书
华润双鹤02月27日获主力加仓1061万元
市场透视 · 02-27
华润双鹤02月27日获主力加仓1061万元
华润双鹤:左炔诺孕酮原料药获得世界卫生组织CPQ证书
每日经济新闻 · 02-26
华润双鹤:左炔诺孕酮原料药获得世界卫生组织CPQ证书
华润双鹤(600062.SH)全资孙公司左炔诺孕酮原料药获得WHO的CPQ证书
智通财经网 · 02-26
华润双鹤(600062.SH)全资孙公司左炔诺孕酮原料药获得WHO的CPQ证书
华润双鹤:公司高度重视环境保护相关工作,积极践行企业社会责任
证券之星 · 02-26
华润双鹤:公司高度重视环境保护相关工作,积极践行企业社会责任
华润双鹤:敬请关注公司于3月20日披露的2024年年度报告
证星董秘互动 · 02-26
华润双鹤:敬请关注公司于3月20日披露的2024年年度报告
华润双鹤:目前公司正积极推进速必一进入医保的准备工作
互动易 · 02-26
华润双鹤:目前公司正积极推进速必一进入医保的准备工作
华润双鹤02月26日主力净流入569万元 散户资金抛售
市场透视 · 02-26
华润双鹤02月26日主力净流入569万元 散户资金抛售
加载更多
公司概况
公司名称:
华润双鹤药业股份有限公司
所属行业:
医药制造业
上市日期:
1997-05-22
主营业务:
华润双鹤药业股份有限公司是主营业务为慢病业务、专科业务和输液业务三大业务。主要产品包括复方利血平氨苯蝶啶片(0号)、胞磷胆碱钠片(诺百益)、苯磺酸氨氯地平片(压氏达)、丙戊酸镁缓释片(神泰)、格列喹酮片(糖适平)、软袋(含直软)、内封式聚丙烯输液。
发行价格:
6.69
{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":19.13,"timestamp":1741676135000,"preClose":19.01,"halted":0,"volume":12068045,"delay":0,"changeRate":0.0063,"floatShares":1027000000,"shares":1039000000,"eps":1.5906,"marketStatus":"交易中","change":0.12,"latestTime":"03-11 14:55:35","open":18.85,"high":19.17,"low":18.71,"amount":229000000,"amplitude":0.0242,"askPrice":19.13,"askSize":6,"bidPrice":19.12,"bidSize":208,"shortable":0,"etf":0,"ttmEps":1.5906,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1741676400000},"marketStatusCode":2,"adr":0,"adjPreClose":19.01,"symbolType":"stock","openAndCloseTimeList":[[1741656600000,1741663800000],[1741669200000,1741676400000]],"highLimit":20.91,"lowLimit":17.11,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038836522,"isCdr":false,"pbRate":1.94,"roa":"--","peRate":12.026908,"roe":"12.39%","epsLYR":1.3002,"committee":-0.391209,"marketValue":19873000000,"turnoverRate":0.0117,"status":0,"floatMarketCap":19651000000},"requestUrl":"/m/hq/s/600062","defaultTab":"news","newsList":[{"id":"2518757411","title":"“体重管理年”刷屏,是为了滞销的减肥药吗?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518757411","media":"医药财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518757411?lang=zh_cn&edition=full","pubTime":"2025-03-10 15:31","pubTimestamp":1741591873,"startTime":"0","endTime":"0","summary":"————————————“体重管理年”主要是政府应对肥胖相关慢性病的健康策略,强调综合管理,而非单纯推销药物。关于“体重管理年”与减肥药市场的关系,需结合政策背景、市场动态及健康管理目标综合分析。结论“体重管理年”的核心目标是提升公众健康意识及慢性病防控能力,减肥药市场的繁荣更多是市场需求与技术发展的结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310193946abf2d434&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310193946abf2d434&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600380","688117","BK0239","BK0028","605116","BK0010","BK0188","BK0185","600196","688131","600867","600276","600721","688166","BK0175","600062","688076","603087"],"gpt_icon":0},{"id":"2517989131","title":"华润双鹤控股子公司阿齐沙坦原料药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2517989131","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517989131?lang=zh_cn&edition=full","pubTime":"2025-03-06 17:23","pubTimestamp":1741253026,"startTime":"0","endTime":"0","summary":"3月6日,华润双鹤发布公告,控股子公司浙江新赛科药业有限公司的阿齐沙坦原料药获得国家药品监督管理局的《化学原料药上市申请批准通知书》。该原料药的批准标志着其符合国家药品审评技术标准,待通过GMP符合性检查后可进入国内市场。截至公告日,公司针对该原料药的累计研发投入为373万元。目前,登记阿齐沙坦原料药的企业共有13家,浙江新赛科在其中。2024年前三季度,华润双鹤实现收入85.48亿元,归母净利润13.97亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306172417963bf9d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306172417963bf9d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0185","BK0188","600062","BK0175","BK0239","BK0010","BK0028"],"gpt_icon":0},{"id":"2517313101","title":"华润双鹤最新公告:控股子公司浙江新赛科阿齐沙坦原料药获得化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2517313101","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517313101?lang=zh_cn&edition=full","pubTime":"2025-03-06 17:21","pubTimestamp":1741252913,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称,公司控股子公司浙江新赛科的阿齐沙坦原料药收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》。该原料药已符合国家相关药品审评技术标准,待通过GMP符合性检查后可生产销售至国内市场,有利于进一步丰富公司的产品线,提升市场竞争力。但该原料药的投产及未来投产后的具体销售情况可能受到国家政策、市场环境变化等因素影响,存在一定的不确定性。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600029693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600062","BK0010","BK0028","BK0175","BK0185"],"gpt_icon":0},{"id":"2517131363","title":"华润双鹤(600062.SH)子公司阿齐沙坦原料药获得化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2517131363","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517131363?lang=zh_cn&edition=full","pubTime":"2025-03-06 17:21","pubTimestamp":1741252898,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华润双鹤(600062.SH)发布公告,近日,公司控股子公司浙江新赛科药业有限公司(以下简称“浙江新赛科”)阿齐沙坦原料药收到了国家药品监督管理局下发的《化学原料药上市申请批准通知书》(通知书编号:2025YS00186)。阿齐沙坦是一款血管紧张素Ⅱ受体拮抗剂(ARB)类抗高血压药物,用于治疗高血压症。浙江新赛科阿齐沙坦原料药取得《化学原料药上市申请批准通知书》,表明该原料药已符合国家相关药品审评技术标准,待通过GMP符合性检查后可生产销售至国内市场,有利于进一步丰富公司的产品线,提升市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0175","BK0010","600062","BK0185","BK0188","BK0028"],"gpt_icon":0},{"id":"2517139719","title":"华润双鹤:控股子公司阿齐沙坦原料药获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517139719","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517139719?lang=zh_cn&edition=full","pubTime":"2025-03-06 17:15","pubTimestamp":1741252510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","BK0175","BK0010","600062","BK0185","BK0188","BK0028"],"gpt_icon":0},{"id":"2517969032","title":"华润双鹤03月05日主力净流出20万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2517969032","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517969032?lang=zh_cn&edition=full","pubTime":"2025-03-05 15:19","pubTimestamp":1741159145,"startTime":"0","endTime":"0","summary":"03月05日, 华润双鹤股价跌1.20%,报收18.96元,成交金额2.04亿元,换手率1.05%,振幅1.51%,量比0.74。华润双鹤今日主力资金净流出20万元,上一交易日主力净流入3137万元。该股近5个交易日上涨2.05%,主力资金累计净流入1426万元;近20日主力资金累计净流出2009万元,其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305153850a26034e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305153850a26034e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0185","BK0188","BK0175","BK0010","600062","BK0239"],"gpt_icon":0},{"id":"2516164635","title":"华润双鹤03月04日主力净流入3137万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2516164635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516164635?lang=zh_cn&edition=full","pubTime":"2025-03-04 15:18","pubTimestamp":1741072687,"startTime":"0","endTime":"0","summary":"03月04日, 华润双鹤股价涨1.59%,报收19.19元,成交金额2.81亿元,换手率1.44%,振幅2.49%,量比1.06。华润双鹤今日主力资金净流入3137万元,上一交易日主力净流出927万元。该股近5个交易日上涨4.12%,主力资金累计净流入2015万元;近20日主力资金累计净流出207万元,其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304152642abe75c97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304152642abe75c97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0010","BK0028","BK0175","600062","BK0188","BK0185","BK0239"],"gpt_icon":0},{"id":"2516168687","title":"华润双鹤:左乙拉西坦口服溶液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2516168687","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516168687?lang=zh_cn&edition=full","pubTime":"2025-03-03 19:37","pubTimestamp":1741001831,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华润双鹤(600062.SH)公告,公司控股子公司湖南省湘中制药有限公司(简称“湘中制药”)收到了国家药品监督管理局颁发的左乙拉西坦口服溶液《药品注册证书》。左乙拉西坦口服溶液是一种用于成人、儿童及一个月以上婴幼儿癫痫患者部分性发作的加用治疗药物。【免责声明】本文仅代表作者本人观点,与和讯网无关。和讯网站对文中陈述、观点判断保持中立,不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考,并请自行承担全部责任。邮箱:news_center@staff.hexun.com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503031942299899dcf5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503031942299899dcf5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0175","BK0188","BK0028","600062","BK0185","BK0010","BK0239"],"gpt_icon":0},{"id":"2516684800","title":"华润双鹤(600062.SH):左乙拉西坦口服溶液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684800","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516684800?lang=zh_cn&edition=full","pubTime":"2025-03-03 19:11","pubTimestamp":1741000291,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华润双鹤(600062.SH)公告,公司控股子公司湖南省湘中制药有限公司(简称“湘中制药”)收到了国家药品监督管理局颁发的左乙拉西坦口服溶液《药品注册证书》。左乙拉西坦口服溶液是一种用于成人、儿童及一个月以上婴幼儿癫痫患者部分性发作的加用治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH):左乙拉西坦口服溶液获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600062","BK0010","BK0175","BK0028","BK0188","BK0239","BK0185"],"gpt_icon":0},{"id":"2516684840","title":"华润双鹤(600062.SH):天东制药通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516684840?lang=zh_cn&edition=full","pubTime":"2025-03-03 19:09","pubTimestamp":1741000187,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华润双鹤(600062.SH)公告,公司控股子公司东营天东制药有限公司(简称“天东制药”)肝素钠原料药、那屈肝素钙原料药收到山东省药品监督管理局颁发的《药品GMP符合性检查告知书》。本次药品GMP符合性检查,是肝素钠原料药新工艺、那屈肝素钙原料药上市前的首次药品GMP符合性检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","600062","BK0010","BK0175","BK0028","BK0239","BK0188","BK1191","01477","BK0185"],"gpt_icon":0},{"id":"2516768509","title":"华润双鹤:产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2516768509","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516768509?lang=zh_cn&edition=full","pubTime":"2025-03-03 18:00","pubTimestamp":1740996011,"startTime":"0","endTime":"0","summary":"每经AI快讯,华润双鹤3月3日晚间发布公告称,近日,华润双鹤药业股份有限公司控股子公司湖南省湘中制药有限公司收到了国家药品监督管理局颁发的左乙拉西坦口服溶液《药品注册证书》。产品名称为“左乙拉西坦口服溶液”。华润双鹤的董事长是陆文超,男,49岁,学历背景为硕士;总裁是赵骞,男,43岁,学历背景为博士。每经头条(nbdtoutiao)——每经专访人社部原副部长杨志明:改变目前中等收入群体中“白领”占多数的状况,让掌握高技术技能的大批优秀“蓝领”进入中等收入群体(记者 曾健辉)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303180102963757df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303180102963757df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600062","BK0010","BK0239","BK0185","BK0175","BK0028","BK0188"],"gpt_icon":0},{"id":"2516686346","title":"华润双鹤最新公告:控股子公司东营天东制药有限公司通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2516686346","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516686346?lang=zh_cn&edition=full","pubTime":"2025-03-03 17:50","pubTimestamp":1740995442,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称,公司控股子公司东营天东制药有限公司近日收到山东省药品监督管理局颁发的《药品GMP符合性检查告知书》,检查范围为原料药(肝素钠、那屈肝素钙)。此次药品GMP符合性检查是肝素钠原料药新工艺、那屈肝素钙原料药上市前的首次检查,未投入资金。肝素钠原料药新工艺已取得国家药品监督管理局下发的《化学原料药上市申请批准通知书》,那屈肝素钙原料药正在审评审批中。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030300026365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0185","BK0239","BK0188","BK0010","01477","BK0028","BK1574","BK0175","BK1191"],"gpt_icon":0},{"id":"2516686827","title":"华润双鹤最新公告:控股子公司湘中制药左乙拉西坦口服溶液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2516686827","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516686827?lang=zh_cn&edition=full","pubTime":"2025-03-03 17:50","pubTimestamp":1740995419,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称,公司控股子公司湖南省湘中制药有限公司收到国家药品监督管理局颁发的左乙拉西坦口服溶液《药品注册证书》。该药品为化学药品4类,规格为150ml:15g,用于成人、儿童及一个月以上婴幼儿癫痫患者部分性发作的加用治疗。湘中制药自2021年启动该药品的仿制药研发工作,于2023年10月提交上市许可申请,2025年2月获得批准上市。根据国家相关政策规定,本次获得《药品注册证书》视同通过一致性评价。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030300026366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","01477","BK1191","BK0175","BK0188","BK0239","BK0185","BK0010","BK0028","600062"],"gpt_icon":0},{"id":"2514873442","title":"华润双鹤02月27日获主力加仓1061万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514873442","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514873442?lang=zh_cn&edition=full","pubTime":"2025-02-27 15:22","pubTimestamp":1740640935,"startTime":"0","endTime":"0","summary":"02月27日, 华润双鹤股价涨1.18%,报收18.80元,成交金额2.77亿元,换手率1.44%,振幅1.83%,量比1.08。华润双鹤今日主力资金净流入1061万元,上一交易日主力净流入569万元。该股近5个交易日上涨1.13%,主力资金累计净流入5329万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出841万元,其中净流出天数为10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227165417a2561037&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227165417a2561037&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0010","600062","BK0239","BK0185","BK0175","BK0028"],"gpt_icon":0},{"id":"2514410881","title":"华润双鹤:左炔诺孕酮原料药获得世界卫生组织CPQ证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2514410881","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514410881?lang=zh_cn&edition=full","pubTime":"2025-02-26 17:09","pubTimestamp":1740560946,"startTime":"0","endTime":"0","summary":"每经AI快讯,华润双鹤(600062)2月26日晚间公告,全资孙公司秦皇岛紫竹药业有限公司(简称“秦皇岛紫竹”)近日收到世界卫生组织(简称“WHO”)签发的左炔诺孕酮原料药(微粉)预资质认证证书(简称“CPQ证书”)。左炔诺孕酮为合成的强效孕激素,为速效、短效避孕药。WHO网站信息显示,目前左炔诺孕酮原料药CPQ证书持有者仅有秦皇岛紫竹一家,公司左炔诺孕酮原料药2023年销售收入为5265.51万元。文章来源:每日经济新闻原标题:华润双鹤:左炔诺孕酮原料药获得世界卫生组织CPQ证书","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226173023abdda063&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226173023abdda063&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600062","BK0028","BK0010","BK0185","BK0188","BK0239","BK0175"],"gpt_icon":0},{"id":"2514883099","title":"华润双鹤(600062.SH)全资孙公司左炔诺孕酮原料药获得WHO的CPQ证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2514883099","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514883099?lang=zh_cn&edition=full","pubTime":"2025-02-26 16:45","pubTimestamp":1740559506,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华润双鹤 公告,近日,公司全资孙公司秦皇岛紫竹药业有限公司收到了世界卫生组织签发的左炔诺孕酮原料 药 预 资 质 认 证 证 书 。据悉,左炔诺孕酮为合成的强效孕激素,为速效、短效避孕药,避孕机制是显著抑制排卵和阻止孕卵着床,并使宫颈粘液稠度增加,精子穿透阻力增大,从而发挥速效避孕作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600062","BK0010","BK0239","BK0185","BK0175","BK0028","BK0188"],"gpt_icon":0},{"id":"2514883623","title":"华润双鹤:公司高度重视环境保护相关工作,积极践行企业社会责任","url":"https://stock-news.laohu8.com/highlight/detail?id=2514883623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514883623?lang=zh_cn&edition=full","pubTime":"2025-02-26 16:30","pubTimestamp":1740558612,"startTime":"0","endTime":"0","summary":"证券之星消息,华润双鹤(600062)02月26日在投资者关系平台上答复投资者关心的问题。投资者:您好!我是一名普通公民,非常关心空气污染问题。我想知道贵公司在日常运营中,是否制定了相关的措施来减少空气污染?我们相信企业的积极参与对改善城市空气质量至关重要华润双鹤董秘:感谢您对公司的关注!公司高度重视环境保护相关工作,积极践行企业社会责任。具体环保情况说明,敬请关注公司定期报告及可持续发展报告。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022600028328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161912","600062","BK0010","BK0175","BK0028","BK0188","BK0239","BK0185"],"gpt_icon":0},{"id":"2514220007","title":"华润双鹤:敬请关注公司于3月20日披露的2024年年度报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2514220007","media":"证星董秘互动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514220007?lang=zh_cn&edition=full","pubTime":"2025-02-26 16:00","pubTimestamp":1740556813,"startTime":"0","endTime":"0","summary":"证券之星消息,华润双鹤02月26日在投资者关系平台上答复投资者关心的问题。什么日期时候发布华润双鹤2024年四季度业绩预告?公司严格遵守《上海证券交易所股票上市规则》及相关法律法规要求,履行信息披露义务。关于四季度净利润等业绩情况,敬请关注公司于3月20日披露的2024年年度报告。投资者:您好,董秘,请问:2024年度业绩年报快报什么时候发?24年4季度营收情况怎么样?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022616060398934690&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022616060398934690&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0028","BK0239","BK0010","600062","BK0175","BK0185"],"gpt_icon":0},{"id":"2514002805","title":"华润双鹤:目前公司正积极推进速必一进入医保的准备工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2514002805","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514002805?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:36","pubTimestamp":1740555362,"startTime":"0","endTime":"0","summary":"有投资者向华润双鹤提问, 请问贵公司独家代理香雷糖足膏(速必一)在大陆什么时候能够进入医保销售,或者进入药店销售,有没有时间表。谢谢!公司回答表示,感谢您对公司的关注!目前公司正积极推进速必一进入医保的准备工作,也在按照自费药积极进行市场拓展。同时,因为速必一治疗的疾病类型与商业保险特点高度吻合,公司先后主动接洽了中国人保寿险等多家行业领先企业,积极探索纳入商业保险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226154610a254833f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226154610a254833f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0185","BK0239","BK0188","BK0010","600062","BK0028","BK0175"],"gpt_icon":0},{"id":"2514879002","title":"华润双鹤02月26日主力净流入569万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2514879002","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514879002?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:18","pubTimestamp":1740554338,"startTime":"0","endTime":"0","summary":"02月26日, 华润双鹤股价涨0.81%,报收18.58元,成交金额1.94亿元,换手率1.02%,振幅1.09%,量比0.72。华润双鹤今日主力资金净流入569万元,上一交易日主力净流出40万元。该股近5个交易日下跌0.05%,主力资金累计净流入3996万元;近20日主力资金累计净流出2616万元,其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226153947abdd7840&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226153947abdd7840&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0010","BK0185","BK0239","600062","BK0028","BK0175","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1741676137727,"stockEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0251},{"period":"3month","weight":-0.0816},{"period":"6month","weight":-0.1035},{"period":"1year","weight":-0.0693},{"period":"ytd","weight":-0.0399}],"compareEarnings":[{"period":"1week","weight":0.0148},{"period":"1month","weight":0.0189},{"period":"3month","weight":-0.0165},{"period":"6month","weight":0.2367},{"period":"1year","weight":0.1051},{"period":"ytd","weight":0.0043}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"40648人(较上一季度减少7.63%)","perCapita":"25271股","listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","registeredCapital":"103883万元","survey":" 华润双鹤药业股份有限公司是主营业务为慢病业务、专科业务和输液业务三大业务。主要产品包括复方利血平氨苯蝶啶片(0号)、胞磷胆碱钠片(诺百益)、苯磺酸氨氯地平片(压氏达)、丙戊酸镁缓释片(神泰)、格列喹酮片(糖适平)、软袋(含直软)、内封式聚丙烯输液。","listedPrice":6.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.5","shortVersion":"4.31.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}